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Abstract
Discovered in 1965, bone morphogenetic proteins (BMPs) are a group of cytokines from the
transforming growth factor-β (TGFβ) superfamily with significant roles in bone and cartilage
formation. BMPs are used as powerful osteoinductive components of diverse tissue-engineering
products for the healing of bone. Several BMPs with different physiological roles have been
identified in humans. The purpose of this review is to cover the biological function of the main
members of BMP family, the latest research on BMPs signalling pathways and advances in the
production of recombinant BMPs for tissue engineering purposes. Copyright  2008 John Wiley &
Sons, Ltd.
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1. Body morphogenetic proteins
Research on bone regeneration began decades ago as a
result of intensive studies on bone growth and healing.
Bone has been recognised, among the many tissues
in human body, as one with the highest potential
for regeneration. As early as 1889 Senn noticed that
decalcified bone could induce healing of bone defects
(Senn, 1889). Later Lavender provided the first evidence
of ectopic bone formation after injecting bone crude
extracts into muscle (Levander, 1934, 1938). In 1965
the pioneering work by Urist marked a landmark on
the research in bone regeneration. Urist discovered that
the active compound responsible for bone regeneration
was a mix of proteins and named these as bone
morphogenetic proteins (BMPs; Urist, 1965). In the years
that followed Sampath and Reddi created a crude but
highly reproducible bioassay for BMP for ectopic bone
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formation (Sampath and Reddi, 1981). The assay was
based on the activity of the enzyme alkaline phosphatase
enzyme and the content of calcium in the newly formed
bone. Reddi proposed that BMPs are responsible for the
initiation of a cascade of developmental events, in which
progenitor cells in the bone marrow were induced by these
factors to produce bone cells leading to bone regeneration
(Reddi and Huggins, 1972; Reddi, 1981).
During the decades of 80s and 90s the BMP genes
were cloned and the recombinant proteins were shown to
be biologically potent (Wozney et al., 1988). Much work
followed with the use of recombinant BMPs (rhBMPs)
for clinical applications such as spinal fusion, fracture
healing and dental tissue engineering (Nakashima and
Reddi, 2003; Seeherman and Wozney, 2005). Human
BMPs are now produced in larger amounts by recombinant
technology. In 2002 FDA gave approval of two products
containing rhBMP-2 and rhBMP-7 in absorbable collagen
carriers for spinal fusion and long bone non-unions
(McKay et al., 2007; White et al., 2007). In a recent review
Reddi proposed naming BMPs also as body morphogenetic
proteins, due to their extensive roles in various tissues and
organs beyond the bone (Reddi, 2005).
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2. Members of the BMP family
In humans several members are under the designation of
BMPs, from BMP-2 to BMP-18 (Table 1). BMP-1 is not a
member of the BMP family. It is a misidentified protein
with chordinase and procollagen proteinase activities,
implicated in embryonic patterning (Kessler et al., 1996).
In fact, since BMPs were named by homology-based
cDNA cloning, there is confusion over BMP designations
and there is a need to develop a more appropriate
nomenclature for the BMP family.
The biological functions of BMPs are mainly related
to bone and cartilage formation (Reddi, 2005), although
BMP-8b, -10 and -15 do not have known roles in bone or
cartilage. BMP-10 is involved in cardiac development and
BMP-15 in ovarian physiology (Chen et al., 2004; Knight
and Glister, 2006). BMP-8b is involved in reproductive
cells (Zhao et al., 1996). Usually only BMP-2 to BMP-
11 are considered to be BMPs. BMP-12, -13 and -
14 are named cartilage-derived morphogenetic proteins
(CDMPs), as these induce chondrogenic phenotypes
rather than osteogenesis (Reddi, 2003). BMPs are also
involved in embryonic patterning (Kishigami and Mishina,
2005), in skeletal formation (Tsumaki and Yoshikawa,
2005) and in organogenesis of other tissues behind bone.
For example, BMP-2 plays a role in heart morphogenesis
(Callis et al., 2005) and in neural stem cells (White
et al., 2001), BMP-7 in kidney formation (Simic and
Vukicevic, 2005) and diverse BMPs have unique roles
in reproductive organs (Shimasaki et al., 2004; Tsumaki
and Yoshikawa, 2005). During the events of early
embryogenesis, BMPs are involved in the dorsal–ventral
patterning with different roles, e.g. BMP-2 and -4 induce
embryo ventral differentiation, while BMP-3 and -3b
oppose the ventralizing effect by inducing tail and
head formation, respectively (Hino et al., 2004). During
gastrulation a BMP gradient in signalling established by
BMP antagonists is responsible for directing cells into
forming organs such as bone, cartilage, kidney or heart,
depending on the levels of BMP activity and of other
cytokines (Yamamoto and Oelgeschlager, 2004). The
pleiotropic effect of the different BMPs is of important
consideration for tissue engineering. For instance, besides
being used for differentiation of cartilage and bone BMP-4
is being studied for a role in keeping the undifferentiated
state in embryonic stem cells (Qi et al., 2004). BMPs
Table 1. BMP members in humans and their main physiological roles
BMP Nomenclature Main physiological roles References
Bone morphogenetic proteins
BMP-2 BMP-2a Cartilage and bone
morphogenesis/heart formation
Wang et al., 1990a; Kang et al.,
2004; Callis et al., 2005
BMP-3 Osteogenin Negative regulator of bone
morphogenesis
Hino et al., 2004
BMP-3b GDF-10 Negative regulator of bone
morphogenesis
Hino et al., 2004
BMP-4 BMP-2b Cartilage and bone
morphogenesis/kidney formation
Luyten et al., 1994; Kubler et al.,
1998a; Oxburgh et al., 2005
BMP-5 – Limb development/bone
morphogenesis
Cho et al., 2002; Zuzarte-Luis et al.,
2004
BMP-6 Vrg1, Dvr6 Hypertrophy of cartilage/bone
morphogenesis/oestrogen mediation
Gitelman et al., 1994; Rickard et al.,
1998; Kang et al., 2004
BMP-7 OP-1 Cartilage and bone
morphogenesis/kidney formation
Reddi, 1998; Kang et al., 2004; Simic
and Vukicevic, 2005
BMP-8 OP-2 Bone
morphogenesis/spermatogenesis
Ozkaynak et al., 1992; Zhao et al.,
1996; Cho et al., 2002
BMP-9 GDF-2 Bone morphogenesis/development
of cholinergic neurons/glucose
metabolism
Chen et al., 2003; Kang et al., 2004;
Lopez-Coviella et al., 2006
BMP-11 GDF-11 Axial skeleton patterning/eye
development/pancreas
development/kidney formation
Esquela and Lee, 2003; Harmon
et al., 2004; Kim et al., 2005;
Andersson et al., 2006
Cartilage-derived morphogenetic proteins
BMP-12 CDMP-3, GDF-7 Ligament and tendon
development/development of
sensory neurons
Reddi, 2003; Lo et al., 2005
BMP-13 CDMP-2, GDF-6 Cartilage development and
hypertrophy
Reddi, 2003
BMP-14 CDMP-1, GDF-5 Chondrogenesis/angiogenesis Yamashita et al., 1997; Reddi, 2003;
Zeng et al., 2007
Others
BMP-8b OP-3 Spertmatogenesis Zhao et al., 1996
BMP-10 – Heart morphogenesis Chen et al., 2004
BMP-15 GDF-9b Ovary physiology Knight and Glister, 2006
BMP-16 Nodal Embryonic patterning Celeste and Murray, 1999
BMP-17 Lefty Embryonic patterning Celeste and Murray, 2000
BMP-18 Lefty Embryonic patterning Celeste and Murray, 2000
BMPs known to induce complete bone morphogenesis are underlined.
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clearly possess pivotal roles in controlling the proliferation
and differentiation fates of cells. In bone formation
a clear bone-inducing role is observed for BMP-2, -
4, -6, -7 and -9. These BMPs have been shown to
induce bone mineralisation and increase in osteocalcin
levels in C2C12 cells (Chen et al., 2003) and orthotopic
ossification in mice (Kang et al., 2004). BMP-3 and -
3b are possibly inhibitors or negative regulators of
osteogenesis, as these downregulate the expression of
ALP in bone cells (Hino et al., 2004). During fracture
healing different BMPs follow specific defined temporal
sequences. BMP-2 appears to be an early factor peaking
at day 1 after fracture while BMP-14 peaks at day 7
during cartilage formation and BMP-3, -4, -7 and -8 are
expressed mainly after 2 weeks (Cho et al., 2002). In
analogy different BMPs are also expressed in site-specific
patterns during the formation of bone (Zoricic et al.,
2003).
2.1. Subgroups within the BMP family
BMPs belong to TGFβ superfamily, which includes
several other growth factors, such as activins, inhibins
or TGFβs. The members of the BMP family may be
subdivided into different subgroups based in their gene
homology and similarity in protein structure (Wozney and
Rosen, 1998; Kishigami and Mishina, 2005; Reddi, 2005;
see Table 2). The proteins within the BMP-2/4 group,
osteogenic protein-1 (OP-1) group, BMP-9/10 group
and BMP-12/13/14 group share sequence similarities of
more than 50%. BMP-11 and BMP-15 are more distant
members, similar to growth differentiation factors -8 and
-9, respectively. Interestingly, the morphogens named as
growth and differentiation factors (GDFs) have similarity
to some BMPs and could therefore be included in the
BMP family. However, these are not described in this
review since their biological roles are beyond bone
induction, except for GDF-3 a BMP inhibitor, and GDF-8,
a negative regulator of bone and muscle mass (Levine
and Brivanlou, 2006; Hamrick et al., 2007). Additionally,
under the term BMP are BMP-16 to -18. These were
given disclosure in patent applications (Celeste and
Murray, 1999, 2000). BMP-16 is a human homologue
to murine Nodal and BMP-17/18 are related to Lefty.
Both have important roles during embryonic patterning,
mainly by antagonising the effect of BMP signalling in
mesoderm formation (Nodal) or for the establishment
of left-right embryonic asymmetry (Lefty) (Meno et al.,
1997; Thisse et al., 2000). Since BMP-16 to -18 are
more distantly related to BMPs than to other TGFβ
superfamily members these should conceivably form a
different group in the TGFβ superfamily, distinct from
BMPs.
3. The structure of BMPs
BMPs as all members of the TGFβ superfamily, are homo
or heterodimers linked via disulphide bridges. These
Table 2. Suggested subgroups within BMP family (grouped by
similarity to OP-1)
Subgroup Members of TGFβ superfamily
OP-1 (BMP-7) BMP-5, -6, -7, -8, -8b
BMP-2/4 BMP-2, -4
CDMP1/2/3 BMP-12, -13, -14 (GDF-5, 6, 7)
BMP-9/10 BMP-9 (GDF-2), BMP-10
BMP-3/3b BMP-3, BMP-3b (GDF-10)
BMP-11/GDF-8 BMP-11 (GDF-11), GDF-8
BMP-15/GDF-9 BMP-15 (GDF-9b), GDF-9
proteins are expressed as large precursor polypeptide
chains containing a hydrophobic signal sequence, a long
and poorly conserved N-terminal pro-region sequence, a
mature domain with a highly conserved C-terminal region
and an N-terminal region that varies among the different
BMPs.
BMPs are biologically active in homodimer and
heterodimer conformation (Israel et al., 1996). BMPs form
a conserved motif of seven cysteines, which is involved
in the formation of six intrachain disulphide bonds and a
single interchain bond, necessary to dimer formation.
Heterodimers in cell cultures have been observed to
induce much higher yields of osteogenic marker alkaline
phosphatase (ALP) (Aono et al., 1995) than homodimeric
BMP. Moreover, BMP-4/7 heterodimers have also been
reported for their very potent mesoderm inducing activity
in Xenopus (Suzuki et al., 1997). A role has been attributed
to heterodimers of BMP-4/8b in primordial germ cell
formation (Ying et al., 2001). In humans, there is evidence
that BMP heterodimers may be also involved in specific
biological processes (Butler and Dodd, 2003), challenging
researchers to look for working with heterodimers
besides the widely documented investigation with BMP
homodimers.
Intracellularly BMPs are produced as precursors that
dissociate after proteolytical cleavage by subtilisin-like
proprotein convertases to form mature proteins (Ge
et al., 2005). However, in some cases the pro-region
remains associated after secretion to the extracellular
space, inhibiting the binding of BMPs to cell receptors.
Importantly, propeptide forms of mature BMPs have been
linked to specific physiological roles, such as in synovial
rheumatoid arthritis for proBMP-2 and proBMP-6 (Lories
et al., 2007), and in the stabilisation of BMPs in the cases
of proBMP-4 (Degnin et al., 2004) and proBMP-9 (Brown
et al., 2005). It is possible that the half-life of mature BMPs
may be influenced by the identity of their prosequences,
and that prodomains serve for other cellular effects
(Gregory et al., 2005) which by itself is an important
consideration for tissue-engineering approaches involving
the use of these morphogens.
3.1. Wrist and knuckle epitopes
During the last years crystallographic studies have
provided insights into the structure of BMPs and their
interaction with receptors upon binding. Crystallographic
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studies have been reported for BMP-7 (Griffith et al.,
1996), BMP-2 (Scheufler et al., 1999) BMP-9 (Scheufler
et al., 1999), BMP-9 (Brown et al., 2005) and BMP-14
(Schreuder et al., 2005). These studies have revealed
a common polypeptide core for BMPs and TGFβ. The
differences in hydrophobic core amongst these BMPs
explain the different affinities for the various cell
receptors and possibly for its different physiological roles
(Allendorph et al., 2006). In BMP-2 two symmetrical pairs
of juxtaposed epitopes were described: the wrist epitope,
with affinity to BMP receptor I (BmprI), containing
residues from both monomers; and the knuckle epitope,
which includes residues from only one monomer, with
low affinity for BMP receptor II (BmprII; Nickel et al.,
2001). Mutations in epitope II lead to loss of activation of
both BMP/Smad pathway and induction of ALP, or even
complete inhibition of its function (Kirsch et al., 2000).
Variants with antagonistic properties are exclusively
generated by mutations in the knuckle epitope of BMP-2.
A synthetic knuckle peptide alone was also sufficient to
induce ALP, osteocalcin and ectopic bone formation in a
rat model (Saito et al., 2003). Alterations in epitope I lead
only to a reduction of ALP activity while activation of the
BMP–Smad pathway is maintained (Knaus and Sebald,
2001). From these findings it was possible to conclude
that the activation of the BMP–Smad pathway and the
induction of early osteogenic marker ALP were triggered
by distinct BMP–receptor complexes. Different pathways
are probably triggered in consequence to the interaction
between the different epitopes of BMPs and cell receptors
(Hassel et al., 2003).
3.2. N-terminal of BMP
Another particular feature of the structure of BMP-2 is
a heparin-binding domain in the N-terminal region of
the mature polypeptide, which modifies its biological
activity (Ruppert et al., 1996). Ruppert and colleagues
demonstrated that the presence of the N-terminus of
BMP-2 reduced its specific activity by interacting with
heparinic sites in the extracellular matrix. A variant of
recombinant BMP-2 was produced without this domain
(EHBMP-2), and biological activity increased five-fold in
a limb bud assay when compared to normal BMP-2 and
was not affected by the presence of heparin. However,
other studies have demonstrated that the presence of
heparin binding site increased region increased retention
times at the site of injury, and that this was necessary
for higher osteoinductive effects (Wurzler et al., 2004). In
a recent work a basic core of only three amino acids in
the N-terminal region of BMP-4 was demonstrated to be
required for its site restriction to the non-neural ectoderm
(Ohkawara et al., 2002). The authors suggested that
heparan sulphate proteoglycans bind to this basic core and
thus play a role in trapping BMP-4. This study was the first
to identify a critical domain responsible for the interaction
between the BMP and the extracellular environment
that restricts its diffusion in vivo. Interestingly, heparan
sulphates were also observed to be required for BMP-7
signalling (Irie et al., 2003) and recently these have been
observed to greatly influence the chondrogenic activity
of BMPs (Fisher et al., 2006) and the transcription of
several osteogenic genes in response to BMP (Manton
et al., 2007). For these reasons heparin has been included
in several different tissue engineering constructs using
BMPs (Jeon et al., 2007; Lin et al., 2008).
3.3. BMP antagonists
There are diverse BMP-binding proteins that act as
modulators of BMP activity or as antagonists, such as
Noggin (Zimmerman et al., 1996), Chordin (Blader et al.,
1997), Follistatin (Fainsod et al., 1997) and Gremlin (Hsu
et al., 1998). These are extracellular regulator proteins
that prevent the BMP assembly to cell receptors and in
this way modulate the effect of BMP signalling during
the formation of tissues. Crystallographic studies showed
that the binding of antagonists, such as Noggin, to BMPs
inhibited its signalling through blocking the binding of
BMP epitopes for type I and type II receptors to which
BMPs bind (Groppe et al., 2002). Recently, two new
cofactors that regulate BMP signalling, Betaglycan and
crypto, were described (Dale et al., 2004). Betaglycan
formed a complex with inhibins which binds to activin
type II receptors, thus preventing BMP signalling (Wiater
and Vale, 2003). Because of the association of these
proteins with various diseases and with additional
biological roles, the generation of antagonists of TGFβ
superfamily members might generate potent tools for
basic research and therapeutic approaches (Gazzerro and
Canalis, 2006).
4. BMP signalling – from cell receptor
to gene activation
BMPs, and all members of the TGFβ superfamily, bind
to serine–threonine kinase receptors on the cell surface,
triggering specific intracellular pathways that activate
and influence gene transcription, having precise effects
in cell proliferation and differentiation (Figure 1). There
are types I, II and III receptors for TGFβ superfamily
members. Only types I and II appear to play significant
roles in BMP binding and signalling, both of which are
required for signal transduction (Heldin et al., 1997; Shi
and Massague, 2003). For the BMP family, significantly
more ligands than receptors are known. To the best of
our knowledge the main receptors to which most BMPs
bind are type I receptors activin receptor Ia (ActR-I or
Alk2), BmprIa (Alk3) and BmprIb (Alk6) and the type
II receptors BMP receptor II (BmprII), activin type II
receptor (ActR-II) and activin type IIB receptor (ActR-IIB)
(Derynck and Zhang, 2003). However, type III TGF-β
receptors have been shown to serve as cell receptors for
BMP signalling, mediating epithelial to mesenchymal cell
conversion (Kirkbride et al. 2008).
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Figure 1. BMP signalling pathways: schematic representation of Smad-dependent and -independent pathways and their main
mechanisms of modulation
Upon BMP binding low-affinity type II receptors are
constitutively activated and type I receptors are activated
by the transphosphorylation of the glycine–serine (GS)-
rich domain of these receptors (Heldin et al., 1997).
Therefore, the specificity of intracellular signals is
mainly determined by type I receptors (Miyazono et al.,
2005). BMP2-binding to preformed receptor complexes
induces the SMAD pathway whereas signalling complexes
sequentially assembled by BMP2 result in the activation
of p38-mitogen-activated protein kinase (MAPK; Hassel
et al., 2003). Different combinations of type I and type
II receptors are the key to providing different and
specific signals which result in different cell effects
(Sebald et al., 2004). In fact, a recent study showed
that Alk3 (type Ia) and Alk6 (type Ib) BMP receptors
may transmit different signals during the specification
and differentiation of mesenchymal lineages (Kaps et al.,
2004). BMP-2 and BMP-4 bind preferentially to Alk3 and
Alk6, whereas the BMP-7 group binds more to Alk2 and
Alk6. BMP-14 (GDF5) binds to Alk6, but not efficiently
to other receptors (Miyazono and Miyazawa, 2002), and
the same is noted for BMP-15 (Shimasaki et al., 2004;
Tsumaki and Yoshikawa, 2005). BMP-13 (GDF6) binds
to Alk3 (Kishigami and Mishina, 2005). All these BMPs
activate Smad-1, -5 and -8 signalling, whereas for TGFβ,
Nodal and activins, Smad-2 and -3 are mainly involved
(Shimasaki et al., 2004; Tsumaki and Yoshikawa, 2005).
Differently, BMP-11 binds to Alk4, -5 and -7 to activate
Smad-3 signalling (Andersson et al., 2006). It has been
shown that BMP-3 binds to Alk4 type I receptor and that it
may block BMP signalling by competing with ActR-IIB and
reducing Smad-1, -5, -8 or Smad-2, -3 phosphorylation
(Gamer et al., 2005). Finally, activin receptor-like kinase
1 (Alk1) was identified as a potential receptor for BMP-
9 (Brown et al., 2005) acting through Smad-1 and -5
signalling (Lopez-Coviella et al., 2006). Mutations in the
BMP receptors have been described to cause diseases.
Mutations in the BmprII gene have been found in patients
with primary pulmonary hypertension (PPH; Lane et al.,
2000); those in the BmprIA gene have been found in
some patients with juvenile polyposis (Howe et al., 2001).
Furthermore, proteomic studies have revealed that the C-
terminal tail of BMP receptors type II is also involved
in the regulation of cytoskeletal proteins (Hassel et al.,
2004). Targeting BMP cell receptors may then be an
alternative way to mediate bone-inducing stimuli in
tissue-engineering approaches.
4.1. BMP/Smad signalling
Smads are the main signal transducers of ser-
ine–threonine receptors (Derynck and Zhang, 2003).
Upon BMP binding, type I receptors phosphorylate
receptor-regulated Smads (R-Smads). Different R-Smads
were identified in mammals: Smad1, Smad5, Smad8
and possibly Smad9 (Xu et al., 2003). Activated R-
Smads form a complex with common-partner Smad
(Co-Smad) (Xu et al., 2003). There is only one described
Co-Smad, Smad4. Two phosphorylated R-Smads form
a heterotrimeric complex with one Co-Smad, which is
translocated into the nucleus and modulates gene tran-
scription with cooperation with other transcription factors
(Massague and Wotton, 2000; Derynck and Zhang, 2003;
Vincent et al., 2003). All R-Smads are activated by BMP-2
or -4, whereas BMP-6, -7 and -9 only efficiently induce
Smad1 and -5 but not Smad8 (Aoki et al., 2001; Brown
et al., 2005). Negative regulation of BMP-induced Smad
signal transduction is modulated by inhibitory Smads (I-
Smads). I-Smads act by inhibiting the activation of type I
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receptors upon BMP binding (Hanyu et al., 2001). Smad6
and -7 act as I-Smads. Smad6 preferentially inhibits BMP
signalling while Smad7 inhibits both TGFβ –activin and
BMP signalling. I-Smads also interact with R-Smads,
preventing the formation of the complex with Smad4
(Murakami et al., 2003) inhibiting the transcription of
specific genes (Edlund et al., 2003). BMP signalling is
also modulated by ubiquitin-dependent protein degrada-
tion. Smad ubiquitin regulatory factors (Smurfs) induce
the ubiquitination and degradation of Smads thus con-
trolling the signal of BMP. Smurfs form a complex with
inhibitory Smad7, which associates with type I recep-
tors, promoting the ubiquitination and degradation of
these receptors (Murakami et al., 2003). Interestingly,
Smurfs also enhance the responsiveness to Smad2, which
mediates TGFβ signalling and has as opposite effect to
that of BMPs (Zhu et al., 1999; Zhang et al., 2001). The
Smad signalling pathway has been also investigated in
cancer treatment (Leivonen and Kahari, 2007; ten Dijke
and Arthur, 2007; Katoh, 2007). By controlling the dif-
ferent Smad signalling and thus specific cell responses,
researchers could in the near future not only achieve a
better knowledge of how BMPs but also modulate the
subtle biological roles inherent to the diverse TGF-β and
BMP members (Schmierer and Hill, 2007).
4.2. BMP/MAPK signalling
Mitogen-activated protein kinase (MAPK) pathways are
alternative pathways that are also implicated in the
signal transduction of BMPs (Derynck and Zhang,
2003; Massague, 2003). There are three characterised
MAPK pathways in mammalian cells: the extracellular-
signal regulated kinases (ERKs); the c-Jun-NH2-terminal
kinases (JNKs); and the p38 MAPK pathways. These
pathways are triggered either by cytokines such as
BMPs or by environmental stress (Tibbles and Woodgett,
1999). Thus it may be of importance for biomedical
purposes that MAPK pathways are considered since these
are connected to a wide range of cellular responses.
Cooperative interactions have been reported between
Smads and transcription factors activated by MAPK
pathways. The X-linked inhibitor of apoptosis links the
BMP receptor signalling to TGFβ1-activated tyrosine
kinase 1 (TAK1) and activates p38 and JNK kinases and
nuclear factor-kappaB (NF-κB) (Silverman et al., 2003;
Takaesu et al., 2003). In osteoprogenitor cells TAK1
interacts with Smads, thus interfering with the BMP
signals and osteogenic differentiation (Hoffmann et al.,
2005). MAPK pathways interact with other pathways
mediated by different cytokines such as epithelial growth
factor (EGF), insulin-like growth factor (IGF) or fibroblast
growth factor (FGF) (Massague, 2003). These act by
extracellular signal-regulated kinases which inhibit the
BMP–Smad signalling through Ras/Raf/Mek (Aubin
et al., 2004). It was reported that during embryonic
differentiation activation of these pathways inhibit the
BMP signalling thus favouring neural differentiation
(Pera et al., 2003). It appears that MAPK pathways
modulate BMP–Smad signalling through interaction with
two conserved globular domains present in Smads, the
MH1 and MH2 domains. The MH1 domain is involved
in DNA binding and the MH2 domain in binding
to cytoplasmic retention factors, activated receptors,
nucleoporins in the nuclear pore, and DNA-binding
cofactors, coactivators and corepressors in the nucleus
(Yamamoto et al., 2003). Recently, it has been shown
that MAPK pathways promoted the termination of Smad-
mediated BMP signalling, in Xenopus (Fuentealba et al.,
2007). The simultaneously application of BMPs and
other cytokines in therapeutical situations may therefore
have specific antagonistic or synergistic effects depending
on the interactions occurring between the signalling
pathways triggered by each growth factor.
4.3. BMP gene modulation
When translocated to the nucleus, Smads regulate gene
transcription by interacting and binding to specific
DNA sequences and DNA-binding proteins, such as
transcriptional factors (Miyazono et al., 2000). BMP-
activated Smads bind preferentially to the GCCGnCGC
sequence of target genes and only weakly to AGAC or
GTCT gene sequences, which are preferentially bound
by TGFβ- or activin-activated Smads (Kusanagi et al.,
2000). Smads also interact with transcriptional factors
and transcriptional coactivators and corepressors.
Runt-related transcription Factor (Runx) is one the
most studied transcription factors for BMP signalling,
regulating processes such as bone formation and
haematopoiesis (Ito and Miyazono, 2003). Three isoforms
have been identified in mammals: Runx1, Runx2 (also
known as Cbfa1, core binding factor A1) and Runx3.
The three are reported to interact with R-Smads. Runx2
cooperatively regulates transcription of genes leading to
the differentiation of mesenchymal progenitor cells into
osteoblasts (Zhang et al., 2000; Miyazono et al., 2004),
and for this reason is widely screened as a marker for
commitment of cells into the osteochondral lineage and
differentiation into bone. Expression levels of Runx2 are
low in mesenchymal cells and are induced upon BMP
signalling (Maeda et al., 2004). The induction of Runx2
is mediated by a balance between two transcription
factors, Dlx5 and Msx2, that responding to BMP signalling,
triggering the activation of Runx2 (Miyama et al., 1999;
Lee et al., 2003, 2005). Diverse osteogenic markers
are then induced by Runx2, such as ALP, osteocalcin,
osteopontin and others (Kumar et al., 2005; Takahashi
et al., 2005), which are closely related to the process of
endochondral calcification.
Osterix (OSX) is another transcription factor that
is mediated by BMP/Smad signals and probably by
MAPK signalling and other pathways (Celil et al., 2005).
Osterix, together with Runx2, are the most studied
transcription factors specific for BMP signalling, involved
in the differentiation of mesenchymal stem cells into
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bone cells (Satija et al., 2007). Smad signalling also
interacts with other proteins such as ATF4, TAZ, and
NFATc1 transcriptional factors (Deng et al, 2008), Hoxc-
8 (Shi et al., 1999), MyoD (Liu et al., 2001), OAZ (Hata
et al., 2000), Msx1 (Yamamoto et al., 2000), and SIP1
(Verschueren et al., 1999). Menin is another required
factor that regulates Runx2-induced transcription of
genes during the early commitment phase of osteoblast
differentiation (Sowa et al., 2004). Among the several
BMP target genes, Id (inhibitor of differentiation or
inhibitor of DNA binding) proteins are some of the
most important ones (Ogata et al., 1993). Id proteins
function as negative regulators of cell differentiation
and as positive regulators of cell proliferation (Yokota,
2001). Recent advances in microarray analysis enable the
identification of many BMP target genes in diverse cell
types (Clancy et al., 2003; Garcia et al., 2002; Korchynskyi
et al., 2003; Kowanetz et al., 2004) and allow a better
understanding of the physiological effects of BMPs.
4.4. Cross-talk with other pathways
BMP signalling is modulated by cross-talk with several
other pathways in a very elaborate network of interacting
molecules. BMP and TGFβ –activin pathways compete
with each other, as they share similar signalling molecules,
such as Smad-4 (Candia et al., 1997). Inhibitory Smads
are also modulated by several other cytokines and
the presence of shear stress in cells (Miyazono et al.,
2000). Expression of endogenous TGFβ in preosteoblastic
differentiation cells induces I-Smads, which regulate
a faster or slower BMP-induced differentiating effect
(Maeda et al., 2004). The BMP–Smad pathway was
also observed to interact in either synergistic or
antagonistic ways with other signalling pathways, such
as the Notch pathway (Dahlqvist et al., 2003), the
EGF pathway (Kretzschmar et al., 1997), the STAT/LIF
pathway (Nakashima et al., 1999), the Wnt pathway
(Nishita et al., 2000), IGF and FGF signalling (Pera
et al., 2003) and in convergence/antagonistic effect
with the MAP kinase pathway (Aubin et al., 2004).
MAPK pathway has also been shown to enhance BMP
signalling in response to collagen stimulus through
activation of the Ras–ERK pathway (Suzawa et al.,
2002). These molecular pathways have been involved
in modulating BMP signalling in diverse cellular effects
and processes, such as osteoblast maturation (Zamurovic
et al., 2004), migration of endothelial cells (Itoh et al.,
2004), epithelial-to-mesenchymal cell transition (Zavadil
et al., 2004) and inhibition of myogenic differentiation
(Dahlqvist et al., 2003).
4.5. Recombinant BMPs for tissue
engineering
After Urist’s pioneering experiments in 1965, BMPs were
extracted and purified from bone of several different
species including rabbit (Urist et al., 1979), cow (Wang
et al., 1988) and human (Urist et al., 1983). Isolation
of native BMP from bone results in very low yields
around 1–2 µg/kg cortical bone. The need for obtaining
larger quantities of BMPs for tissue engineering prompted
researchers to produce and purify these growth factors by
DNA recombinant technology (Table 3).
Nowadays, recombinant BMPs are produced mainly
by two expression systems: in mammalian cells or in
bacteria. With mammalian cells the recombinant protein
is obtained active but yields are usually very low. With
bacteria the protein is obtained in much larger yields but
usually in non-soluble inactive inclusion bodies which
are later solubilised and refolded to yield bioactive
protein. A common disadvantage is that the protein is
not glycosylated as is normal in the human body and thus
may present reduced stability or biological activity.
Recombinant human BMP-2 was first obtained in
mammalian cell cultures from Chinese hamster ovary
(CHO) cells (Wang et al., 1990a). The rhBMP-2 induced
ectopic bone and cartilage formation when implanted
Table 3. Selected works reporting the production of recombinant BMPs in diverse expression systems
BMP Expression system Novelty References
BMP2 CHO cells Bone formation, characterisation of
expressed BMP-2
Wang et al., 1990b; Israel et al.,
1992
BMP2 Insect cells Alternative expression system Maruoka et al., 1995
BMP2 E. coli The heparin binding domain reduces ALP
and specific in vitro biological activity
Ruppert et al., 1996
BMP2 E. coli High density expression in bacteria Li et al., 1998
BMP2 E. coli, pCYTEXP3 Optimisation of refolding conditions for
BMP-2
Vallejo et al., 2002; Vallejo and
Rinas, 2004
BMP2 E. coli Additional heparin binding domains
enhance in vivo bone formation
Wurzler et al., 2004.
BMP2 E. coli, pET-11a Comparison with BMP-2 propeptide Hillger et al., 2005
BMP2 E. coli, pET-21a Use of different refolding buffers Long et al., 2006
BMP2 E. coli, pET-25b Bioactivity in human stem cells Bessa et al., 2008
BMP4 E. coli Bone formation in mice Kubler et al., 1998a
BMP4 E. coli, pET-11a Stability in physiological buffer Klosch et al., 2005
BMP6 E. coli, pET-15b Induction of several osteogenic markers Yang et al., 2003
BMP7 CHO cells Bioactivity in rats Sampath et al., 1992
BMP2/7, 4/7 CHO cells Heterodimer expression Israel et al., 1996
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in rats after 2 weeks. Characterization of rhBMP-2
produced in CHO cells led to the conclusion that the
protein was secreted in three forms, a propeptide of
40–45 kDa, a mature homodimer of 30 kDa and a small
portion of uncleaved precursor of 60 kDa (Israel et al.,
1992). The mature peptide possessed N-glycosylation.
Sampath et al. confirmed the bioactivity of rhBMP-7 from
CHO cells by analysis of bone formation and specific
osteogenic markers, such as osteocalcin (Sampath et al.,
1992). Koenig et al. (1994) noticed a strong tendency of
recombinant BMP-2 to adhere non-specifically to culture
dishes or to the negatively charged extracellular matrix
via its positively charged N-terminal. They modified the
BMP by a mild trypsin digestion, removing the first seven
to nine residues, and named it digit-removed BMP-2, that
still binds to the BMP receptor. Nowadays, commercial
recombinant human BMP-2 lack this N-terminal heparin-
binding end, since the region decreases the specific
bioactivity of the BMP (Ruppert et al., 1996).
In 1996, various combinations of rhBMPs were co-
expressed in CHO cells to test for possible heterodimer
formation (Israel et al., 1996). Transient co-expression
between the different rhBMPs resulted in more bioactivity
than expression of any single rhBMP. The rhBMP-2/7
heterodimer yielded 20-fold higher activity in the in vivo
ALP assay. In 1998 Kubler and colleagues produced
rhBMP-2 and -4 in Escherichia coli and rhBMPs were tested
in a collagen carrier and induced bone formation in rats
after 4 weeks (Kubler et al., 1998a, 1998b). Recombinant
human BMP-6 was later expressed and purified in E. coli
(Yang et al., 2003), using pET-15b vector. The protein
was obtained in inclusion bodies, refolded and induced
ALP activity in C3H10T1/2 cells and other osteogenic
markers, as observed by RT–PCR.
During the last years, Vallejo and colleagues reported
interesting works regarding the production of rhBMP-
2 in inclusion bodies, with optimized protein refolding
procedures (Vallejo et al., 2002; Vallejo and Rinas, 2004).
The group found that refolding of BMP-2 was particularly
sensitive to pH, temperature and concentration, but not so
much to ionic strength or redox conditions. The rhBMP-2
was refolded in buffer with L-arginine or CHES at pH 8.5
to a yield of 750 mg dimer per litre of bacteria growing
media.
In 2005, mature rhBMP-2, unprocessed rhBMP-2 and
propeptide of rhBMP-2 were produced in E. coli (Hillger
et al., 2005), using a pET-11a expression vector. This
group reported bioactivity from both the propeptide and
an N-terminal truncated BMP-2 form. Curiously, in 2004,
Wurzler and co-workers used mutants of rhBMP-2 with
enhanced heparin binding sites (in the N-terminus) and
a variant with no heparin binding site. The variant with
no binding site showed great reduction in osteoinduction,
while the mutants with additional heparin binding sites
led to enhanced bone formation, due to longer retention
times of the BMP-2 in the extracellular matrix (Wurzler
et al., 2004; Depprich et al., 2005). This fact could be
of great interest for drug-delivery approaches providing
recombinant proteins with increased affinity for binding
to the extracellular matrix itself in vivo. In 2005, rat
BMP-4 has been expressed and purified as inclusion
bodies in Escherichia coli that are stable in a physiological
compatible buffer showing bioactivity in MC3T3-E1 cells
(Klosch et al., 2005).
A report on the production of rhBMP-2 was published
in 2006, using pET-21a in E. coli. The protein, obtained in
inclusion bodies, was refolded in different folding buffers
(Long et al., 2006). RhBMP-2 was best refolded at low
concentrations (0.1 mg/ml), 4 ◦C and in the presence
of L-arginine. Recently, soluble rhBMP-2 was obtained
upon production with the use of pET25b E. coli vector.
The rhBMP-2 showed bioactivity in primary cultures of
human fat-derived stem cells and an increase in levels of
osteogenic markers Runx2, Osterix and Smad-1 and -5 in
the C2C12 cell line (Bessa et al., 2008).
5.1. From manufacture of BMPs to
tissue-engineering products
Since their discovery in 1965, BMPs have revealed a
promising future in the field of tissue engineering as
powerful components of biomedical products for the
regeneration of body parts of human patients, namely
bone and cartilage. At present, the state of the art of
regenerative medicine envisages the use of growth factors,
loaded into scaffolding materials and using precursor or
stem cells, possibly from the patient him/herself. It is
expected that future advances in fundamental biology
will allow researchers to design novel tissue-engineering
strategies that make use of combinations of different BMPs
and other growth factors. The use of these growth factor
cocktails will certainly present a challenging approach in
tissue engineering since much is still poorly understood
about the orchestration of molecular cascades underlying
the regeneration of tissues.
Currently, there are two products approved by the
Food and Drug Administration (FDA) consisting of
recombinant BMP-2 and BMP-7 loaded into absorbable
collagen sponges for clinical use for fusion of spinal
vertebrae and treatment of long bone fractures (McKay
et al., 2007; White et al., 2007). However, a whole set
of other less understood BMPs will probably make its
way into the clinic, such as with the case of cartilage-
derived morphogenetic proteins (BMP-12, -13 and -14)
for cartilage or tendon reconstruction, or BMP-9 that has
stronger osteogenic potencies compared to other BMPs
(Kang et al. 2004). Recombinant BMPs used in clinics are
derived from mammalian expression cells, which elevates
much of the cost of clinical products containing rhBMPs.
It is expected that advances in recombinant technology
namely those involving the large-scale production of BMPs
in bacteria will allow researchers to obtain and use these
proteins at a much lower cost.
At present, recombinant technology is also a useful
tool to achieve molecular modifications of BMPs to
improve their bioactivity, stability and affinity to both
the tissue-engineering scaffold or the extracellular
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Table 4. Chemical or genetic engineering modifications for improving particular characteristics of BMPs for use in tissue engineering
applications
Modification process Advantages References
Enzymatic cleavage of BMP heparin
binding domain
Reduces non-specific interactions with
extracellular matrix, leading to increased
bioactivity in vitro
Koenig et al., 1994; Uludag et al.,
2001
Plasmin enzymatic cleavage of BMP Reduces non-specific interactions with
extracellular matrix, leading to increased
bioactivity in vitro
Israel et al., 1992; Hollinger et al.,
1998
Adding additional heparin binding
domains
Increases retention to extracellular matrix or
affinity to biomaterial, leading to increased
activity in vivo
Wurzler et al., 2004; Depprich et al.,
2005
Immobilisation of synthetic peptides
of partial BMP sequences
Improves the stability and specific activity of
the BMP and reduces the initial burst release
Suzuki et al., 2000; Saito et al.,
2003, 2004, 2005; Saito et al., 2006;
Seol et al., 2006; Bergeron et al.,
2007; Park et al., 2007
Fusion protein BMP with domain to
bind a specific biomaterial
Increases the retention of BMP on carrier,
accelerating tissue regeneration; increases
stability and activity of the BMP
Han et al., 2002; Schmoekel et al.,
2005
Fusion protein BMP with RGD for
enhanced cell attachment or domain
for other specific biological function
Enhances attachment of cells, tissue
regeneration and possibly the
biocompatibility of the material
Not yet reported
Chemical modification of BMP, such
as with succinylation, acetylation or
biotinylation, changes the isoelectric
point
Enhances the affinity for binding to the
biomaterial by changing the peptide
solubility, to suit a desired release profile
Hollinger et al., 1998; Uludag et al.,
1999a; Uludag et al., 1999b; Uludag
et al., 2000; Uludag et al., 2001
Formation of heterodimers between
different BMPs
The increased bioactivity of BMP
heterodimers leads to lower dose
Zhu et al., 2006 Aono et al., 1995;
Israel et al., 1996
matrix and cells (see Table 4). For example, by
adding additional heparin binding domains, there is
a significantly different bioactivity and bioavailability
of the rhBMP, decreasing its specific activity in vitro
but increasing bone formation in vivo (Depprich et al.,
2005). Currently, most recombinant BMP-2 and BMP-7
are produced with no heparin binding domain and
thus may present reduced bioactivity when used for
clinical uses. Another approach may consist of producing
recombinant peptides containing only the binding sites
to the cell receptors thus achieving specific biological
effects with no problems derived from loss of bioactivity
or stability which occur during the incorporation into
the scaffold (Suzuki et al., 2000; Saito et al., 2003, 2004,
2005, 2006). Designing chimeric proteins is a further
powerful approach which may include the addition
of other domains of biological importance such as
immune modulatory agents, RGD for increased cell
attachment, GFP for in vivo localization, or domains for
specific binding to biomaterials such as for example
to collagen (Han et al., 2002) or to fibrin (Schmoekel
et al., 2005). Naturally, the chimeric rhBMPs would
have different refolding characteristics as compared
to native proteins. These could have altered stability,
solubility, surface binding and bioactivity/biospecificity
thus making an appealing approach of producing specific-
tissue target proteins and with increased bioactivity
(Oppermann et al., 2005). Chemical modification also
improves binding, stability, bioactivity and bioavailability
of BMPs (Luginbuehl et al., 2004). Thus, by chemically
or recombinantly modifying the isoelectric point of the
BMP the affinity of the BMPs to the delivery matrices
could be greatly enhanced that allows the achievement
of a desired release profile. Chemically modified rhBMP-2
with enhanced affinity to carriers has been reported by
succinylation (Hollinger et al., 1998), acetylation (Uludag
et al., 2000) and biotinylation (Uludag et al., 1999b).
Finally, the expression of recombinant BMP heterodimers
is another way of obtaining these growth factors with
much increased bioactivity (Aono et al., 1995; Israel et al.,
1996).
Despite being promising recombinant technology is
still at as early stage, since there is a need to bypass
some fundamental limitations, such as optimising the
stability and bioactivity of recombinant BMPs, obtaining
glycosylation patterns identical to that of native BMP,
and reducing the possibility of triggering immunogenic
responses when used in clinical situations. In the next
years, the combination of advances of the BMP field with
that of biomaterial science (Mano et al., 2007) will surely
herald a revealing future for the use of these morphogens
for biomedical and tissue-engineering applications.
Acknowledgements
The author wishes to thank Johan Benesch and Isabel Joa˜o for
critical reviewing of the manuscript. This work was supported
by Fundac¸a˜o para a Cieˆncia e Tecnologia (PhD Grant No.
SFRH/BD/17049/2004) and carried out under the scope of
the European NoE EXPERTISSUES (NMP3-CT-2004-500283).
This study was performed according to ethical guidelines. No
conflicts of interest are stated.
References
Andersson O, Reissmann E, Ibanez CF. 2006; Growth differentiation
factor 11 signals through the transforming growth factor-beta
Copyright  2008 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2008; 2: 1–13.
DOI: 10.1002/term
10 P. C. Bessa et al.
receptor ALK5 to regionalize the anterior–posterior axis. EMBO
Rep 7: 831–837.
Aoki H, Fujii M, Imamura T, et al. 2001; Synergistic effects of
different bone morphogenetic protein type I receptors on alkaline
phosphatase induction. J Cell Sci 114: 1483–1489.
Aono A, Hazama M, Notoya K, et al. 1995; Potent ectopic
bone-inducing activity of bone morphogenetic protein–4/7
heterodimer. Biochem Biophys Res Commun 210: 670–677.
Aubin J, Davy A, Soriano P. 2004; In vivo convergence of BMP
and MAPK signaling pathways: impact of differential Smad1
phosphorylation on development and homeostasis. Genes Dev 18:
1482–1494.
Bergeron E, Marquis ME, Chretien I, et al. 2007; Differentiation of
preosteoblasts using a delivery system with BMPs and bioactive
glass microspheres. J Mater Sci Mater Med 18: 255–263.
Bessa PC, Pedro AJ, Klosch B, et al. 2008; Osteoinduction in human
fat-derived stem cells by recombinant human bone morphogenetic
protein-2 produced in Escherichia coli, Biotechnol Lett, 30: 15–21.
Blader P, Rastegar S, Fischer N, et al. 1997; Cleavage of the BMP-4
antagonist chordin by zebrafish tolloid. Science 278: 1937–1940.
Brown MA, Zhao Q, Baker KA, et al. 2005; Crystal structure of BMP-
9 and functional interactions with pro-region and receptors. J Biol
Chem 280: 25111–25118.
Butler SJ, Dodd J. 2003; A role for BMP heterodimers in roof plate-
mediated repulsion of commissural axons. Neuron 38: 389–401.
Callis TE, Cao D, Wang DZ. 2005; Bone morphogenetic protein
signaling modulates myocardin transactivation of cardiac genes.
Circ Res 97: 992–1000.
Candia AF, Watabe T, Hawley SH, et al. 1997; Cellular interpretation
of multiple TGFβ signals: intracellular antagonism between
activin/BVg1 and BMP-2/4 signaling mediated by Smads.
Development 124: 4467–4480.
Celeste AJ, Murray BL. 1999; Nucleic acids encoding bone
morphogenic protein-16 (BMP-16). US Patent No. 596503.
Celeste AJ, Murray BL. 2000; Bone morphogenetic protein (BMP)-17
and BMP-18 compositions. US Patent No. 6027917.
Celil AB, Hollinger JO, Campbell PG. 2005; Osx transcriptional
regulation is mediated by additional pathways to BMP2/Smad
signaling. J Cell Biochem 95: 518–528.
Chen C, Grzegorzewski KJ, Barash S, et al. 2003; An integrated
functional genomics screening program reveals a role for BMP-9
in glucose homeostasis. Nat Biotechnol 21: 294–301.
Chen H, Shi S, Acosta L, et al. 2004; BMP10 is essential for
maintaining cardiac growth during murine cardiogenesis.
Development 131: 2219–2231.
Cho TJ, Gerstenfeld LC, Einhorn TA. 2002; Differential temporal
expression of members of the transforming growth factor beta
superfamily during murine fracture healing. J Bone Miner Res 17:
513–520.
Clancy BM, Johnson JD, Lambert AJ, et al. 2003; A gene expression
profile for endochondral bone formation: oligonucleotide
microarrays establish novel connections between known genes
and BMP-2-induced bone formation in mouse quadriceps. Bone
33: 46–63.
Dahlqvist C, Blokzijl A, Chapman G, et al. 2003; Functional Notch
signaling is required for BMP4-induced inhibition of myogenic
differentiation. Development 130: 6089–6099.
Dale RA, Harrison JS, Redding SW. 2004; Oral complications in
cancer chemotherapy, cancer incidence, and mortality in the US.
Gen Dent 52: 64–71; quiz, 72.
Degnin C, Jean F, Thomas G, et al. 2004; Cleavages within the
prodomain direct intracellular trafficking and degradation of
mature bone morphogenetic protein-4. Mol Biol Cell 15:
5012–5020.
Depprich R, Handschel J, Sebald W, et al. 2005; [Comparison of
the osteogenic activity of bone morphogenetic protein (BMP)
mutants]. Mund Kiefer Gesichtschir 9: 363–368 [in German].
Derynck R, Zhang YE. 2003; Smad-dependent and Smad-
independent pathways in TGFβ family signalling. Nature 425:
577–584.
Edlund S, Bu S, Schuster N, et al. 2003; Transforming growth factor-
beta1 (TGFβ)-induced apoptosis of prostate cancer cells involves
Smad7-dependent activation of p38 by TGFβ-activated kinase 1
and mitogen-activated protein kinase kinase 3. Mol Biol Cell 14:
529–544.
Esquela AF, Lee SJ. 2003; Regulation of metanephric kidney
development by growth/differentiation factor 11. Dev Biol 257:
356–370.
Fainsod A, Deissler K, Yelin R, et al. 1997; The dorsalizing and neural
inducing gene follistatin is an antagonist of BMP-4. Mech Dev 63:
39–50.
Fisher MC, Li Y, Seghatoleslami MR, et al. 2006; Heparan sulfate
proteoglycans including syndecan-3 modulate BMP activity during
limb cartilage differentiation. Matrix Biol 25: 27–39.
Gamer LW, Nove J, Levin M, et al. 2005; BMP-3 is a novel inhibitor
of both activin and BMP-4 signaling in Xenopus embryos. Dev Biol
285: 156–168.
Ge G, Hopkins DR, Ho WB, et al. 2005; GDF11 forms a bone
morphogenetic protein 1-activated latent complex that can
modulate nerve growth factor-induced differentiation of PC12
cells. Mol Cell Biol 25: 5846–5858.
Gitelman SE, Kobrin MS, Ye JQ, et al. 1994; Recombinant Vgr-
1/BMP-6-expressing tumors induce fibrosis and endochondral
bone formation in vivo. J Cell Biol 126: 1595–1609.
Gregory KE, Ono RN, Charbonneau NL, et al. 2005; The prodomain
of BMP-7 targets the BMP-7 complex to the extracellular matrix. J
Biol Chem 280: 27970–27980.
Griffith DL, Keck PC, Sampath TK, et al. 1996; Three-dimensional
structure of recombinant human osteogenic protein 1: structural
paradigm for the transforming growth factor beta superfamily.
Proc Natl Acad Sci USA 93: 878–883.
Groppe J, Greenwald J, Wiater E, et al. 2002; Structural basis of BMP
signalling inhibition by the cystine knot protein Noggin. Nature
420: 636–642.
Hamrick MW, Shi X, Zhang W, et al. 2007; Loss of myostatin (GDF8)
function increases osteogenic differentiation of bone marrow-
derived mesenchymal stem cells but the osteogenic effect is ablated
with unloading. Bone 40: 1544–1553.
Han B, Perelman N, Tang B, et al. 2002; Collagen-targeted BMP3
fusion proteins arrayed on collagen matrices or porous ceramics
impregnated with type I collagen enhance osteogenesis in a rat
cranial defect model. J Orthop Res 20: 747–755.
Hanyu A, Ishidou Y, Ebisawa T, et al. 2001; The N domain of Smad7
is essential for specific inhibition of transforming growth factor-
beta signaling. J Cell Biol 155: 1017–1027.
Harmon EB, Apelqvist AA, Smart NG, et al. 2004; GDF11 modulates
NGN3+ islet progenitor cell number and promotes β cell
differentiation in pancreas development. Development 131:
6163–6174.
Hassel S, Eichner A, Yakymovych M, et al. 2004; Proteins associated
with type II bone morphogenetic protein receptor (BMPR-II)
and identified by two-dimensional gel electrophoresis and mass
spectrometry. Proteomics 4: 1346–1358.
Hassel S, Schmitt S, Hartung A, et al. 2003; Initiation of Smad-
dependent and Smad-independent signaling via distinct BMP-
receptor complexes. J Bone Joint Surg Am 85A(suppl 3): 44–51.
Hata A, Seoane J, Lagna G, et al. 2000; OAZ uses distinct DNA-
and protein-binding zinc fingers in separate BMP–Smad and Olf
signaling pathways. Cell 100: 229–240.
Heldin CH, Miyazono K, ten Dijke P. 1997; TGFβ signalling from
cell membrane to nucleus through SMAD proteins. Nature 390:
465–471.
Hillger F, Herr G, Rudolph R, et al. 2005; Biophysical comparison of
BMP-2, ProBMP-2, and the free pro-peptide reveals stabilization
of the pro-peptide by the mature growth factor. J Biol Chem 280:
14974–14980.
Hino J, Kangawa K, Matsuo H, et al. 2004; Bone morphogenetic
protein-3 family members and their biological functions. Front
Biosci 9: 1520–1529.
Hoffmann A, Preobrazhenska O, Wodarczyk C, et al. 2005;
Transforming growth factor-beta-activated kinase-1 (TAK1), a
MAP3K, interacts with Smad proteins and interferes with
osteogenesis in murine mesenchymal progenitors. J Biol Chem
280: 27271–27283.
Hollinger JO, Uludag H, Winn SR. 1998; Sustained release
emphasizing recombinant human bone morphogenetic protein-2.
Adv Drug Deliv Rev 31: 303–318.
Howe JR, Bair JL, Sayed MG, et al. 2001; Germline mutations of the
gene encoding bone morphogenetic protein receptor 1A in juvenile
polyposis. Nat Genet 28: 184–187.
Hsu DR, Economides AN, Wang X, et al. 1998; The Xenopus
dorsalizing factor Gremlin identifies a novel family of secreted
proteins that antagonize BMP activities. Mol Cell 1: 673–683.
Irie A, Habuchi H, Kimata K, et al. 2003; Heparan sulfate is required
for bone morphogenetic protein-7 signaling. Biochem Biophys Res
Commun 308: 858–865.
Copyright  2008 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2008; 2: 1–13.
DOI: 10.1002/term
Bone morphogenetic proteins in tissue engineering, part I 11
Israel DI, Nove J, Kerns KM, et al. 1996; Heterodimeric bone
morphogenetic proteins show enhanced activity in vitro and
in vivo. Growth Factors 13: 291–300.
Israel DI, Nove J, Kerns KM, et al. 1992; Expression and
characterization of bone morphogenetic protein-2 in Chinese
hamster ovary cells. Growth Factors 7: 139–150.
Ito Y, Miyazono K. 2003; RUNX transcription factors as key targets
of TGFβ superfamily signaling. Curr Opin Genet Dev 13: 43–47.
Itoh F, Itoh S, Goumans MJ, et al. 2004; Synergy and antagonism
between Notch and BMP receptor signaling pathways in
endothelial cells. EMBO J 23: 541–551.
Kang Q, Sun MH, Cheng H, et al. 2004; Characterization of the
distinct orthotopic bone-forming activity of 14 BMPs using
recombinant adenovirus-mediated gene delivery. Gene Ther 11:
1312–1320.
Kaps C, Hoffmann A, Zilberman Y, et al. 2004; Distinct roles of BMP
receptors type IA and IB in osteo-/chondrogenic differentiation in
mesenchymal progenitors (C3H10T1/2). Biofactors 20: 71–84.
Kessler E, Takahara K, Biniaminov L, et al. 1996; Bone
morphogenetic protein-1: the type I procollagen C-proteinase.
Science 271: 360–362.
Kim J, Wu HH, Lander AD, et al. 2005; GDF11 controls the timing
of progenitor cell competence in developing retina. Science 308:
1927–1930.
Kirsch T, Nickel J, Sebald W. 2000; BMP-2 antagonists emerge from
alterations in the low-affinity binding epitope for receptor BMPR-II.
EMBO J 19: 3314–3324.
Kishigami S, Mishina Y. 2005; BMP signaling and early embryonic
patterning. Cytokine Growth Factor Rev 16: 265–278.
Klosch B, Furst W, Kneidinger R, et al. 2005; Expression and
purification of biologically active rat bone morphogenetic protein-
4 produced as inclusion bodies in recombinant Escherichia coli.
Biotechnol Lett 27: 1559–1564.
Knaus P, Sebald W. 2001; Cooperativity of binding epitopes and
receptor chains in the BMP/TGFβ superfamily. Biol Chem 382:
1189–1195.
Knight PG, Glister C. 2006; TGFβ superfamily members and ovarian
follicle development. Reproduction 132: 191–206.
Koenig BB, Cook JS, Wolsing DH, et al. 1994; Characterization and
cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells.
Mol Cell Biol 14: 5961–5974.
Korchynskyi O, Dechering KJ, Sijbers AM, et al. 2003; Gene array
analysis of bone morphogenetic protein type I receptor-induced
osteoblast differentiation. J Bone Miner Res 18: 1177–1185.
Kowanetz M, Valcourt U, Bergstrom R, et al. 2004; Id2 and Id3
define the potency of cell proliferation and differentiation
responses to transforming growth factor beta and bone
morphogenetic protein. Mol Cell Biol 24: 4241–4254.
Kretzschmar M, Doody J, Massague J. 1997; Opposing BMP and
EGF signalling pathways converge on the TGFβ family mediator
Smad1. Nature 389: 618–622.
Kubler NR, Moser M, Berr K, et al. 1998a; [Biological activity of
E. coli expressed BMP-4]. Mund Kiefer Gesichtschir 2(suppl 1):
S149–152.
Kubler NR, Reuther JF, Faller G, et al. 1998b; Inductive properties
of recombinant human BMP-2 produced in a bacterial expression
system. Int J Oral Maxillofac Surg 27: 305–309.
Kumar S, Mahendra G, Ponnazhagan S. 2005; Determination of
osteoprogenitor-specific promoter activity in mouse mesenchymal
stem cells by recombinant adeno-associated virus transduction.
Biochim Biophys Acta 1731: 95–103.
Kusanagi K, Inoue H, Ishidou Y, et al. 2000; Characterization of a
bone morphogenetic protein-responsive Smad-binding element.
Mol Biol Cell 11: 555–565.
Lane KB, Machado RD, Pauciulo MW, et al. 2000; Heterozygous
germline mutations in BMPR2, encoding a TGFβ receptor, cause
familial primary pulmonary hypertension. The International PPH
Consortium. Nat Genet 26: 81–84.
Lee MH, Kim YJ, Kim HJ, et al. 2003; BMP-2-induced Runx2
expression is mediated by Dlx5, and TGFβ1 opposes the BMP-
2-induced osteoblast differentiation by suppression of Dlx5
expression. J Biol Chem 278: 34387–34394.
Lee MH, Kim YJ, Yoon WJ, et al. 2005; Dlx5 specifically regulates
Runx2 type II expression by binding to homeodomain-response
elements in the Runx2 distal promoter. J Biol Chem 280:
35579–35587.
Levander G. 1934; On the formation of new bone in bone
transplantation. Acta Chir Scand 74: 425–426.
Levander G. 1938; A study of bone regeneration. Surg Gynecol Obstet
67: 705–714.
Levine AJ, Brivanlou AH. 2006; GDF3, a BMP inhibitor, regulates cell
fate in stem cells and early embryos. Development 133: 209–216.
Li M, Chen C, Pu Q, et al. 1998; Production of human recombinant
bone morphogenetic protein-2A by high density culture of
Escherichia coli with stationary dissolved oxygen fed-batch
condition. Chin J Biotechnol 14: 157–163.
Liu D, Black BL, Derynck R. 2001; TGFβ inhibits muscle
differentiation through functional repression of myogenic
transcription factors by Smad3. Genes Dev 15: 2950–2966.
Lo L, Dormand EL, Anderson DJ. 2005; Late-emigrating neural crest
cells in the roof plate are restricted to a sensory fate by GDF7. Proc
Natl Acad Sci USA 102: 7192–7197.
Long L, MacLean MR, Jeffery TK, et al. 2006; Serotonin increases
susceptibility to pulmonary hypertension in BMPR2-deficient mice.
Circ Res 98: 818–827.
Lopez-Coviella I, Mellott TM, Kovacheva VP, et al. 2006;
Developmental pattern of expression of BMP receptors and Smads
and activation of Smad1 and Smad5 by BMP9 in mouse basal
forebrain. Brain Res 1088: 49–56.
Lories RJ, Derese I, de Bari C, et al. 2007; Evidence for uncoupling
of inflammation and joint remodeling in a mouse model of
spondylarthritis. Arthrit Rheum 56: 489–497.
Luginbuehl V, Meinel L, Merkle HP, et al. 2004; Localized delivery
of growth factors for bone repair. Eur J Pharm Biopharm 58:
197–208.
Luyten FP, Chen P, Paralkar V, et al. 1994; Recombinant bone
morphogenetic protein-4, transforming growth factor-beta 1,
and activin A enhance the cartilage phenotype of articular
chondrocytes in vitro. Exp Cell Res 210: 224–229.
Maeda S, Hayashi M, Komiya S, et al. 2004; Endogenous TGFβ
signaling suppresses maturation of osteoblastic mesenchymal cells.
EMBO J 23: 552–563.
Mano JF, Silva GA, Azevedo HS, et al. 2007; Natural origin
biodegradable systems in tissue engineering and regenerative
medicine: present status and some moving trends. J R Soc Interface
4: 999–1030.
Maruoka Y, Oida S, Iimura T, et al. 1995; Production of functional
human bone morphogenetic protein-2 using a Baculovirus system.
J Dent Res 74: 568–568.
Massague J. 2003; Integration of Smad and MAPK pathways: a link
and a linker revisited. Genes Dev 17: 2993–2997.
Massague J, Wotton D. 2000; Transcriptional control by the
TGFβ/Smad signaling system. EMBO J 19: 1745–1754.
Meno C, Ito Y, Saijoh Y, et al. 1997; Two closely-related left-right
asymmetrically expressed genes, lefty-1 and lefty-2: their distinct
expression domains, chromosomal linkage and direct neuralizing
activity in Xenopus embryos. Genes Cells 2: 513–524.
Miyama K, Yamada G, Yamamoto TS, et al. 1999; A BMP-inducible
gene, dlx5, regulates osteoblast differentiation and mesoderm
induction. Dev Biol 208: 123–133.
Miyazono K, Maeda S, Imamura T. 2004; Coordinate regulation of
cell growth and differentiation by TGFβ superfamily and Runx
proteins. Oncogene 23: 4232–4237.
Miyazono K, Maeda S, Imamura T. 2005; BMP receptor signaling:
transcriptional targets, regulation of signals, and signaling cross-
talk. Cytokine Growth Factor Rev 16: 251–263.
Miyazono K and Miyazawa K. 2002; Id: a target of BMP signaling.
Science signaling, 2002: PE40.
Miyazono K, ten Dijke P, Heldin CH. 2000; TGFβ signaling by Smad
proteins. Adv Immunol 75: 115–157.
Murakami G, Watabe T, Takaoka K, et al. 2003; Cooperative
inhibition of bone morphogenetic protein signaling by Smurf1
and inhibitory Smads. Mol Biol Cell 14: 2809–2817.
Nakashima K, Yanagisawa M, Arakawa H, et al. 1999; Synergistic
signaling in fetal brain by STAT3–Smad1 complex bridged by
p300. Science 284: 479–482.
Nakashima M, Reddi AH. 2003; The application of bone
morphogenetic proteins to dental tissue engineering. Nat
Biotechnol 21: 1025–1032.
Nickel J, Dreyer MK, Kirsch T, et al. 2001; The crystal structure
of the BMP-2:BMPR-IA complex and the generation of BMP-2
antagonists. J Bone Joint Surg Am 83A(suppl 1): S7–14.
Nishita M, Hashimoto MK, Ogata S, et al. 2000; Interaction between
Wnt and TGFβ signalling pathways during formation of Spemann’s
organizer. Nature 403: 781–785.
Ogata T, Wozney JM, Benezra R, et al. 1993; Bone morphogenetic
protein-2 transiently enhances expression of a gene, Id (inhibitor
Copyright  2008 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2008; 2: 1–13.
DOI: 10.1002/term
12 P. C. Bessa et al.
of differentiation), encoding a helix–loop–helix molecule in
osteoblast-like cells. Proc Natl Acad Sci USA 90: 9219–9222.
Ohkawara B, Iemura S, ten Dijke P, et al. 2002; Action range of BMP
is defined by its N-terminal basic amino acid core. Curr Biol 12:
205–209.
Oppermann H, Tai M, McCartney J. 2005; Modified proteins of the
TGFβ superfamily, including morphogenic proteins/US Patent No.
6846906.
Oxburgh L, Dudley AT, Godin RE, et al. 2005; BMP4 substitutes for
loss of BMP7 during kidney development. Dev Biol 286: 637–646.
Ozkaynak E, Schnegelsberg PN, Jin DF, et al. 1992; Osteogenic
protein-2. A new member of the transforming growth factor-
beta superfamily expressed early in embryogenesis. J Biol Chem
267: 25220–25227.
Park JB, Lee JY, Park HN, et al. 2007; Osteopromotion with synthetic
oligopeptide-coated bovine bone mineral in vivo. J Periodontol 78:
157–163.
Pera EM, Ikeda A, Eivers E, et al. 2003; Integration of IGF, FGF, and
anti-BMP signals via Smad1 phosphorylation in neural induction.
Genes Dev 17: 3023–3028.
Qi X, Li TG, Hao J, et al. 2004; BMP4 supports self-renewal of
embryonic stem cells by inhibiting mitogen-activated protein
kinase pathways. Proc Natl Acad Sci USA 101: 6027–6032.
Reddi AH. 1981; Cell biology and biochemistry of endochondral
bone development. Coll Relat Res 1: 209–226.
Reddi AH. 1998; Cartilage-derived morphogenetic proteins and
cartilage morphogenesis. Microsc Res Technol 43: 131–136.
Reddi AH. 2003; Cartilage morphogenetic proteins: role in joint
development, homoeostasis, and regeneration. Ann Rheum Dis
62(suppl 2): ii73–78.
Reddi AH. 2005; BMPs: from bone morphogenetic proteins to body
morphogenetic proteins. Cytokine Growth Factor Rev 16: 249–250.
Reddi AH, Huggins C. 1972; Biochemical sequences in the
transformation of normal fibroblasts in adolescent rats. Proc Natl
Acad Sci USA 69: 1601–1605.
Rickard DJ, Hofbauer LC, Bonde SK, et al. 1998; Bone
morphogenetic protein-6 production in human osteoblastic cell
lines. Selective regulation by oestrogen. J Clin Invest 101:
413–422.
Ruppert R, Hoffmann E, Sebald W. 1996; Human bone
morphogenetic protein 2 contains a heparin-binding site which
modifies its biological activity. Eur J Biochem 237: 295–302.
Saito A, Suzuki Y, Kitamura M, et al. 2006; Repair of 20 mm long
rabbit radial bone defects using BMP-derived peptide combined
with an α-tricalcium phosphate scaffold. J Biomed Mater Res A 77:
700–706.
Saito A, Suzuki Y, Ogata S, et al. 2003; Activation of osteo-
progenitor cells by a novel synthetic peptide derived from the
bone morphogenetic protein-2 knuckle epitope. Biochim Biophys
Acta 1651: 60–67.
Saito A, Suzuki Y, Ogata S, et al. 2004; Prolonged ectopic
calcification induced by BMP-2-derived synthetic peptide. J Biomed
Mater Res A 70: 115–121.
Saito A, Suzuki Y, Ogata S, et al. 2005; Accelerated bone repair with
the use of a synthetic BMP-2-derived peptide and bone-marrow
stromal cells. J Biomed Mater Res A 72: 77–82.
Sampath TK, Maliakal JC, Hauschka PV, et al. 1992; Recombinant
human osteogenic protein-1 (hOP-1) induces new bone formation
in vivo with a specific activity comparable with natural bovine
osteogenic protein and stimulates osteoblast proliferation and
differentiation in vitro. J Biol Chem 267: 20352–20362.
Sampath TK, Reddi AH. 1981; Dissociative extraction and
reconstitution of extracellular matrix components involved in local
bone differentiation. Proc Natl Acad Sci USA 78: 7599–7603.
Satija NK, Gurudutta GU, Sharma S, et al. 2007; Mesenchymal stem
cells: molecular targets for tissue engineering. Stem Cells Dev 16:
7–23.
Scheufler C, Sebald W, Hulsmeyer M. 1999; Crystal structure of
human bone morphogenetic protein-2 at 2.7 A resolution. J Mol
Biol 287: 103–115.
Schmoekel HG, Weber FE, Schense JC, et al. 2005; Bone repair with
a form of BMP-2 engineered for incorporation into fibrin cell
ingrowth matrices. Biotechnol Bioeng 89: 253–262.
Schreuder H, Liesum A, Pohl J, et al. 2005; Crystal structure of
recombinant human growth and differentiation factor 5: evidence
for interaction of the type I and type II receptor-binding sites.
Biochem Biophys Res Commun 329: 1076–1086.
Sebald W, Nickel J, Zhang JL, et al. 2004; Molecular recognition
in bone morphogenetic protein (BMP)/receptor interaction. Biol
Chem 385: 697–710.
Seeherman H, Wozney JM. 2005; Delivery of bone morphogenetic
proteins for orthopedic tissue regeneration. Cytokine Growth Factor
Rev 16: 329–345.
Senn N. 1889; On the healing of aseptic bone cavities by implantation
of antiseptic decalcified bone. Am J Med Sci 98: 219–243.
Seol YJ, Park YJ, Lee SC, et al. 2006; Enhanced osteogenic
promotion around dental implants with synthetic binding motif
mimicking bone morphogenetic protein (BMP)-2. J Biomed Mater
Res A 77: 599–607.
Shi X, Yang X, Chen D, et al. 1999; Smad1 interacts with homeobox
DNA-binding proteins in bone morphogenetic protein signaling. J
Biol Chem 274: 13711–13717.
Shi Y, Massague J. 2003; Mechanisms of TGFβ signaling from cell
membrane to the nucleus. Cell 113: 685–700.
Shimasaki S, Moore RK, Otsuka F, et al. 2004; The bone
morphogenetic protein system in mammalian reproduction. Endocr
Rev 25: 72–101.
Silverman N, Zhou R, Erlich RL, et al. 2003; Immune activation of
NF-κB and JNK requires Drosophila TAK1. J Biol Chem 278:
48928–48934.
Simic P, Vukicevic S. 2005; Bone morphogenetic proteins in
development and homeostasis of kidney. Cytokine Growth Factor
Rev 16: 299–308.
Sowa H, Kaji H, Hendy GN, et al. 2004; Menin is required for bone
morphogenetic protein 2- and transforming growth factor beta-
regulated osteoblastic differentiation through interaction with
Smads and Runx2. J Biol Chem 279: 40267–40275.
Suzawa M, Tamura Y, Fukumoto S, et al. 2002; Stimulation of
Smad1 transcriptional activity by Ras-extracellular signal-
regulated kinase pathway: a possible mechanism for collagen-
dependent osteoblastic differentiation. J Bone Miner Res 17:
240–248.
Suzuki A, Kaneko E, Maeda J, et al. 1997; Mesoderm induction by
BMP-4 and -7 heterodimers. Biochem Biophys Res Commun 232:
153–156.
Suzuki Y, Tanihara M, Suzuki K, et al. 2000; Alginate hydrogel
linked with synthetic oligopeptide derived from BMP-2 allows
ectopic osteoinduction in vivo. J Biomed Mater Res 50: 405–409.
Takaesu G, Surabhi RM, Park KJ, et al. 2003; TAK1 is critical for IκB
kinase-mediated activation of the NF-κB pathway. J Mol Biol 326:
105–115.
Takahashi T, Kato S, Suzuki N, et al. 2005; Autoregulatory
mechanism of Runx2 through the expression of transcription
factors and bone matrix proteins in multipotential mesenchymal
cell line, ROB-C26. J Oral Sci 47: 199–207.
Thisse B, Wright CV, Thisse C. 2000; Activin- and Nodal-related
factors control antero-posterior patterning of the zebrafish embryo.
Nature 403: 425–428.
Tibbles LA, Woodgett JR. 1999; The stress-activated protein kinase
pathways. Cell Mol Life Sci 55: 1230–1254.
Tsumaki N, Yoshikawa H. 2005; The role of bone morphogenetic
proteins in endochondral bone formation. Cytokine Growth Factor
Rev 16: 279–285.
Uludag H, D’Augusta D, Golden J, et al. 2000; Implantation
of recombinant human bone morphogenetic proteins
with biomaterial carriers: a correlation between protein
pharmacokinetics and osteoinduction in the rat ectopic model.
J Biomed Mater Res 50: 227–238.
Uludag H, Friess W, Williams D, et al. 1999a; rhBMP-collagen
sponges as osteoinductive devices: effects of in vitro sponge
characteristics and protein pI on in vivo rhBMP pharmacokinetics.
Ann N Y Acad Sci 875: 369–378.
Uludag H, Gao T, Porter TJ, et al. 2001; Delivery systems for BMPs:
factors contributing to protein retention at an application site. J
Bone Joint Surg Am 83-A(suppl 1): S128–135.
Uludag H, Golden J, Palmer R, et al. 1999b; Biotinated bone
morphogenetic protein-2: in vivo and in vitro activity. Biotechnol
Bioeng 65: 668–672.
Urist MR. 1965; Bone: formation by autoinduction. Science 150:
893–899.
Urist MR, Mikulski A, Lietze A. 1979; Solubilized and insolubilized
bone morphogenetic protein. Proc Natl Acad Sci USA 76:
1828–1832.
Urist MR, Sato K, Brownell AG, et al. 1983; Human bone
morphogenetic protein (hBMP). Proc Soc Exp Biol Med 173:
194–199.
Copyright  2008 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2008; 2: 1–13.
DOI: 10.1002/term
Bone morphogenetic proteins in tissue engineering, part I 13
Vallejo LF, Brokelmann M, Marten S, et al. 2002; Renaturation
and purification of bone morphogenetic protein-2 produced as
inclusion bodies in high-cell-density cultures of recombinant
Escherichia coli. J Biotechnol 94: 185–194.
Vallejo LF, Rinas U. 2004; Optimized procedure for renaturation of
recombinant human bone morphogenetic protein-2 at high protein
concentration. Biotechnol Bioeng 85: 601–609.
Verschueren K, Remacle JE, Collart C, et al. 1999; SIP1, a novel zinc
finger/homeodomain repressor, interacts with Smad proteins and
binds to 5′-CACCT sequences in candidate target genes. J Biol
Chem 274: 20489–20498.
Vincent SD, Dunn NR, Hayashi S, et al. 2003; Cell fate decisions
within the mouse organizer are governed by graded Nodal signals.
Genes Dev 17: 1646–1662.
Wang EA, Rosen V, Cordes P, et al. 1988; Purification and
characterization of other distinct bone-inducing factors. Proc Natl
Acad Sci USA 85: 9484–9488.
Wang EA, Rosen V, D’Alessandro JS, et al. 1990a; Recombinant
human bone morphogenetic protein induces bone formation. Proc
Natl Acad Sci USA 87: 2220–2224.
Wang EA, Rosen V, Dalessandro JS, et al. 1990b; Recombinant
human bone morphogenetic protein induces bone formation. Proc
Natl Acad Sci USA 87: 2220–2224.
White PM, Morrison SJ, Orimoto K, et al. 2001; Neural crest stem
cells undergo cell-intrinsic developmental changes in sensitivity to
instructive differentiation signals. Neuron 29: 57–71.
Wiater E, Vale W. 2003; Inhibin is an antagonist of bone
morphogenetic protein signaling. J Biol Chem 278: 7934–7941.
Wozney JM and Rosen V. 1998; Bone morphogenetic protein and
bone morphogenetic protein gene family in bone formation and
repair, Clin Orthop Relat Res, 346: 26–37.
Wozney JM, Rosen V, Celeste AJ, et al. 1988; Novel regulators of
bone formation: molecular clones and activities. Science 242:
1528–1534.
Wurzler KK, Emmert J, Eichelsbacher F, et al. 2004; [Evaluation
of the osteoinductive potential of genetically modified BMP-2
variants]. Mund Kiefer Gesichtschir 8: 83–92 [in German].
Xu XL, Dai KR, Tang TT. 2003; [The role of Smads and related
transcription factors in the signal transduction of bone
morphogenetic protein inducing bone formation]. Zhongguo Xiu
Fu Chong Jian Wai Ke Za Zhi 17: 359–362 [in Chinese].
Yamamoto M, Takahashi Y, Tabata Y. 2003; Controlled release by
biodegradable hydrogyels enhances the ectopic bone formation of
bone morphogenetic protein. Biomaterials 24: 4375–4383.
Yamamoto TS, Takagi C, Ueno N. 2000; Requirement of Xmsx-1 in
the BMP-triggered ventralization of Xenopus embryos. Mech Dev
91: 131–141.
Yamamoto Y, Oelgeschlager M. 2004; Regulation of bone
morphogenetic proteins in early embryonic development.
Naturwissenschaften 91: 519–534.
Yamashita H, Shimizu A, Kato M, et al. 1997; Growth/differentiation
factor-5 induces angiogenesis in vivo. Exp Cell Res 235: 218–226.
Yang JH, Zhao L, Yang S, et al. 2003; [Expression of recombinant
human BMP-6 in Escherichia coli and its purification and bioassay
in vitro]. ShengWu Gong Cheng Xue Bao 19: 556–560 [in Chinese].
Ying Y, Qi X, Zhao GQ. 2001; Induction of primordial germ cells
from murine epiblasts by synergistic action of BMP4 and BMP8B
signaling pathways. Proc Natl Acad Sci USA 98: 7858–7862.
Yokota Y. 2001; Id and development. Oncogene 20: 8290–8298.
Zamurovic N, Cappellen D, Rohner D, et al. 2004; Coordinated
activation of notch, Wnt, and transforming growth factor-beta
signaling pathways in bone morphogenic protein 2-induced
osteogenesis. Notch target gene Hey1 inhibits mineralization and
Runx2 transcriptional activity. J Biol Chem 279: 37704–37715.
Zavadil J, Cermak L, Soto-Nieves N, et al. 2004; Integration of
TGFβ/Smad and Jagged1/Notch signalling in epithelial-to-
mesenchymal transition. EMBO J 23: 1155–1165.
Zeng Q, Li X, Beck G, et al. 2007; Growth and differentiation factor-
5 (GDF-5) stimulates osteogenic differentiation and increases
vascular endothelial growth factor (VEGF) levels in fat-derived
stromal cells in vitro. Bone 40: 374–381.
Zhang Y, Chang C, Gehling DJ, et al. 2001; Regulation of Smad
degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc
Natl Acad Sci USA 98: 974–979.
Zhang YW, Yasui N, Ito K, et al. 2000; A RUNX2/PEBP2α
A/CBFA1 mutation displaying impaired transactivation and Smad
interaction in cleidocranial dysplasia. Proc Natl Acad Sci USA 97:
10549–10554.
Zhao GQ, Deng K, Labosky PA, et al. 1996; The gene encoding bone
morphogenetic protein 8B is required for the initiation and
maintenance of spermatogenesis in the mouse. Genes Dev 10:
1657–1669.
Zhu H, Kavsak P, Abdollah S, et al. 1999; A SMAD ubiquitin ligase
targets the BMP pathway and affects embryonic pattern formation.
Nature 400: 687–693.
Zimmerman LB, De Jesus-Escobar JM, Harland RM. 1996; The
Spemann organizer signal noggin binds and inactivates bone
morphogenetic protein 4. Cell 86: 599–606.
Zoricic S, Maric I, Bobinac D, et al. 2003; Expression of bone
morphogenetic proteins and cartilage-derived morphogenetic
proteins during osteophyte formation in humans. J Anat 202:
269–277.
Zuzarte-Luis V, Montero JA, Rodriguez-Leon J, et al. 2004; A new
role for BMP5 during limb development acting through the
synergic activation of Smad and MAPK pathways. Dev Biol 272:
39–52.
Copyright  2008 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2008; 2: 1–13.
DOI: 10.1002/term
